GSK acquires Novartis for 10.6B
British pharmaceutical company GSK announced its acquisition of the American company Novalent, specialized in cancer treatment, for $10.6 billion as part of its plan to expand its presence in the oncology sector in the United States. The deal includes three lung cancer drugs currently in clinical trials, with FDA approvals expected this year for the new treatments. This acquisition aims to strengthen GSK's position in the US market and to achieve growth in its profits and revenues, despite the company's stock dropping 3.6 percent during trading.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading